Identification of the B-cell tumor-specific molecular fingerprint using non-radiolabelled PCR consensus primers

Annals of Oncology

Volumn 12, Issue 10, 2001, Pages 1479-1484

  Bendandi, M ^a   Tonelli, R ^b   Maffei, R ^b   Botti, S ^b   Turi, C ^b   Sartini, R ^b   Inoges S ^a   Rodriguez Calvillo M ^a   Zinzani, P L ^b   Pession, A ^b   Pileri, S A ^b   Paolucci, G ^b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CDR3; Consensus primers; Follicular lymphoma; PCR; Tumor specific

Indexed keywords

IMMUNOGLOBULIN CLASS; IMMUNOGLOBULIN HEAVY CHAIN;

ARTICLE; B CELL LYMPHOMA; BACTERIUM; BIOPSY; CELL INFILTRATION; CELL SPECIFICITY; CLINICAL ARTICLE; CLONING; COMPLEMENTARITY DETERMINING REGION; COMPLEMENTARITY DETERMINING REGION 3; CONTROLLED STUDY; FAMILY; FEASIBILITY STUDY; FOLLICULAR LYMPHOMA; GENETIC CODE; HUMAN; HUMAN CELL; HUMAN TISSUE; HYBRIDOMA; IMMUNOGLOBULIN VARIABLE REGION; INTERMETHOD COMPARISON; ISOTOPE LABELING; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELIABILITY; SEQUENCE ANALYSIS;

BASE SEQUENCE; DNA FINGERPRINTING; DNA PRIMERS; DNA, COMPLEMENTARY; DNA, NEOPLASM; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN HEAVY CHAINS; LYMPHOMA, B-CELL; LYMPHOMA, FOLLICULAR; MOLECULAR SEQUENCE DATA; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SOFTWARE; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 0035191644     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012586905273     Document Type: Article

References (21)

1. Multiple mechanisms participate in the generation of diversity of human H chain CDR 3 regions
2. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors
3. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma - Long-term results of a clinical trial
4. Idiotypic vaccination against human B-cell lymphoma. Rescue of variable region gene sequences from biopsy material for assembly as single-chain Fv personal vaccines
5. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma
6. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
7. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma
8. Development of vaccine strategies for the treatment of B-cell malignancies
9. Preferential use of the VH4 Ig gene family by diffuse large-cell lymphoma
10. Idiotype immunization combined with granulocyte-macrophage colony-stimulating factor in myeloma patients induced type-I, mayor histocompatibility complex-restricted, CD8- and CD4-specific T-cell responses
11. Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: Comparison of different vaccine formulations
12. Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies
13. Polymerase chain reaction-based detection of minimal residual disease in multiple myeloma patients receiving allogeneic stem cell transplantation
14. Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone
15. Mouse x human heterohybridomas as fusion partners with human B-cell tumors
16. Optimal primer selection for clonality assessment by polymerase chain reaction analysis: I. Low grade B-cell lymphoproliferative disorders of nonfollicular center cell type
17. Automated DNA sequencing
18. Anti-idiotype vaccines for human follicular lymphoma
19. Molecular monitoring of minimal residual disease in patients in long-term complete remission after allogeneic stem cell transplantation for multiple myeloma
20. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma
21. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group